Ardelyx, Inc.

NASDAQ:ARDX

Biotechnology

Healthcare
$3.12 -1.03%

-$0.06 today

Market cap
$784.28M
Beta
0.58
P/E (TTM)
-24.5
EPS (TTM)
-$0.24
52W Low $3.49High $8.40

Volume 4.75M

Average 3.58M

ARDX Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Ardelyx, Inc.NASDAQ: ARDX

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns negative

Q1 FY2026 accounts receivables was -$10.99M, compared with $11.24M a year earlier. Trailing-twelve-month accounts receivables was -$36.37M. Over 3 fiscal years it compounded at +25.1% a year.

Context

  • Accounts receivables amounted to 3.5% of revenue in FY2025, down 7.2 pp from a year earlier.
  • Accounts receivables grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly accounts receivables holds near -$10.99M or moves back toward the trailing-twelve-month quarterly average of -$9.09M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$10.99M-330.8% QoQ
Last fiscal yearDec 2025
-$14.14M-60.4% YoY
LTMMar 2026
-$36.37M+98.7% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-197.8%——
1 year-60.4%——
3-year CAGR+25.1%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(14.14M) USD
Year-over-year change
+60.4%

Accounts Receivables vs competitors

How ARDX compares with its peers on the latest reported figures

  • ARDX's LTM Mar 2026 accounts receivables of $36.37M is the largest of the 5 companies compared; the peer median is $5.97M.
  • Its year-over-year change of +98.7% is the highest of 4, against a peer median of -94.6%.
  • Accounts receivables amounts to 8.5% of revenue for ARDX, versus a peer median of 3.2%.
ARDX Competitors Peer median
Accounts Receivables for ARDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARDXArdelyx, Inc.LTM Mar 2026$36.37M +98.7%+25.1%8.5%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$20M ——100.0%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$9.97M +11.8%-7.4%3.2%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$1.97M -94.6%—0.8%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$49.73K -134.1%——
Peer median (excluding ARDX) $5.97M-94.6%-7.4%3.2%

Competitors are the stored peer set for ARDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(158.17M)(67.21M)(66.07M)(39.14M)(61.6M)
Depreciation & Amortization1.44M1.14M1.29M2.06M3.06M
Deferred Income Tax(190K)0000
Stock-Based Compensation12.04M10.75M13.53M37.38M48.96M
Change in Working Capital(11.92M)(19.58M)(43.39M)(49.17M)(31.35M)
Accounts Receivables(502K)(7.23M)(14.3M)(35.67M)(14.14M)
Inventory(10.37M)(28.35M)(21.14M)(41.7M)(31.92M)
Accounts Payables(1.35M)6.58M279K4.86M3.24M
Other Working Capital300K9.42M(8.23M)23.34M11.48M
Other Non-Cash Items4.25M4.84M4.91M4.05M(1.55M)
Operating Cash Flow(152.55M)(70.04M)(89.72M)(44.81M)(42.48M)
Capital Expenditures(1.87M)(55K)(344K)(1.01M)(1.49M)
Acquisitions (Net)(52.82M)0000
Purchases of Investments(72.74M)(50.33M)(215.23M)(195.16M)(218.92M)
Sales of Investments125.55M67M84.32M177.85M211.46M
Other Investing Activities52.82M1.8M000
Investing Cash Flow50.95M18.42M(131.25M)(18.32M)(8.96M)
Debt Repayment(19.44M)(6.07M)22.39M99.45M48.67M
Common Stock Issued101.15M71.63M119.24M8.14M5.84M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.3M9.78M4.67M(1M)0
Financing Cash Flow83M75.34M146.3M106.59M54.51M
Effect of Forex Changes00000
Net Change in Cash(18.6M)23.71M(74.67M)43.46M3.07M
Free Cash Flow(154.42M)(70.1M)(90.06M)(45.82M)(43.98M)

Ardelyx, Inc.

NASDAQ:ARDX

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.